Sabratek purchasing controls for pre-filled syringes inadequate, FDA says in Dec. 12 warning letter.
This article was originally published in The Gray Sheet
SABRATEK PURCHASING CONTROLS FOR IV FLUSH SYRINGES INADEQUATE, FDA SAYS in a Dec. 12 warning letter to the company. The agency cites Sabratek's Woburn, Massachusetts-based Rocap facility for failing to test incoming products such as syringe, heparin injection, and saline injection components. In addition, "suppliers of incoming product are neither audited nor under any written agreement." The warning letter follows an inspection conducted between Aug. 28 and Sept. 29.
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.